文献速递胸部肿瘤

Alectinib对比化疗用于克唑替尼经治ALK阳性NSCLC的III期ALUR研究

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
PubMed 文献 · Ann Oncol · 2018-01-01

ALUR是一项随机、多中心、开放标签III期试验,在经铂类双药化疗和克唑替尼治疗的晚期/转移性ALK阳性NSCLC患者中比较阿来替尼与化疗。共107例患者随机(阿来替尼72例,化疗35例)。阿来替尼显著改善研究者评估的PFS(9.6个月 vs 1.4个月,HR 0.15,P<0.001)和CNS客观缓解率(54.2% vs 0%,P<0.001),且安全性更优。

要点

  • 阿来替尼较化疗显著延长研究者评估PFS(9.6 vs 1.4个月,HR 0.15)。
  • 基线可测量CNS病灶患者中,阿来替尼CNS ORR为54.2%,化疗为0%。
  • ≥3级不良事件阿来替尼27.1%,化疗41.2%。

核心结论

  • 对于克唑替尼经治的ALK阳性NSCLC患者,阿来替尼较化疗显著改善全身和CNS疗效,且安全性良好。

研究设计与样本

  • ALUR(MO29750;NCT02604342)为随机、多中心、开放标签III期试验,比较阿来替尼与化疗。
  • 入组为经铂类双药化疗和克唑替尼治疗后进展或不耐受的晚期/转移性ALK阳性NSCLC患者。
  • 患者按2:1随机接受阿来替尼600 mg每日两次或化疗(培美曲塞500 mg/m2或多西他赛75 mg/m2,每3周一次)。
  • 共107例患者随机(阿来替尼72例,化疗35例),来自欧洲和亚洲13个国家。
  • 主要终点为研究者评估的无进展生存期(PFS)。

主要发现

  • 研究者评估中位PFS:阿来替尼9.6个月(95%CI 6.9-12.2),化疗1.4个月(95%CI 1.3-1.6),HR 0.15(95%CI 0.08-0.29),P<0.001。
  • 独立评审委员会评估中位PFS:阿来替尼7.1个月(95%CI 6.3-10.8),化疗1.6个月(95%CI 1.3-4.1),HR 0.32(95%CI 0.17-0.59)。
  • 基线可测量CNS疾病患者中(阿来替尼24例,化疗16例),CNS客观缓解率阿来替尼54.2%,化疗0%,P<0.001。
  • ≥3级不良事件发生率:化疗41.2%,阿来替尼27.1%。
  • 导致停药的不良事件发生率:阿来替尼5.7%,化疗8.8%;阿来替尼治疗持续时间更长(20.1周 vs 6.0周)。

临床怎么用

  • 对于克唑替尼治疗后进展或不耐受的ALK阳性晚期NSCLC患者,阿来替尼可作为化疗之上的有效选择。
  • 基线存在可测量CNS病灶的患者,阿来替尼显示更高的CNS客观缓解率。
  • 阿来替尼的≥3级不良事件和导致停药的不良事件发生率低于化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients who have progressed on, or were intolerant to, crizotinib. PATIENTS AND METHODS: ALUR (MO29750; NCT02604342) was a randomized, multicenter, open-label, phase III trial of alectinib versus chemotherapy in advanced/metastatic ALK-positive NSCLC patients previously treated with platinum-based doublet chemotherapy and crizotinib. Patients were randomized 2 : 1 to receive alectinib 600 mg twice daily or chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks) until disease progression, death, or withdrawal. Primary end point was investigator-assessed progression-free survival (PFS). RESULTS: Altogether, 107 patients were randomized (alectinib, n = 72; chemotherapy, n = 35) in 13 countries across Europe and Asia. Median investigator-assessed PFS was 9.6 months [95% confidence interval (CI): 6.9-12.2] with alectinib and 1.4 months (95% CI: 1.3-1.6) with chemotherapy [hazard ratio (HR) 0.15 (95% CI: 0.08-0.29); P < 0.001]. Independent Review Committee-assessed PFS was also significantly longer with alectinib [HR 0.32 (95% CI: 0.17-0.59); median PFS was 7.1 months (95% CI: 6.3-10.8) with alectinib and 1.6 months (95% CI: 1.3-4.1) with chemotherapy]. In patients with measurable baseline central nervous system (CNS) disease (alectinib, n = 24; chemotherapy, n = 16), CNS objective response rate was significantly higher with alectinib (54.2%) versus chemotherapy (0%; P < 0.001). Grade ≥3 adverse events were more common with chemotherapy (41.2%) than alectinib (27.1%). Incidence of AEs leading to study-drug discontinuation was lower with alectinib (5.7%) than chemotherapy (8.8%), despite alectinib treatment duration being longer (20.1 weeks versus 6.0 weeks). CONCLUSION: Alectinib significantly improved systemic and CNS efficacy versus chemotherapy for crizotinib-pretreated ALK-positive NSCLC patients, with a favorable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov NCT02604342; Roche study MO29750.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018. PMID: 29668860. doi:10.1093/annonc/mdy121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。